that the in silico model is suited to the rapid, accurate, determination of Ki values, using MK571 as a prototypical pan-ABCC inhibitor. In vitro-derived data is often used to predict in vivo response, and we have examined how differences in protein expression levels between these systems may impact upon chemical disposition. We show that ABCC2 and ABCC3 are over-expressed in sandwich culture hepatocytes by 3.5-and 2.3-fold respectively at the protein level. Correction for this in markedly different disposition of CDF, with the AUC and Cmax of intracellular CDF increasing by 365% and 160% respectively. Finally, using kinetic simulations we show that ABCC2 represents a fragile node within this pathway, with alterations in ABCC2 having the most prominent effects on both the Km and Vmax through the pathway. This is the first demonstration of the utility of modelling approaches to estimate the impact of drug transport processes on chemical disposition.
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Introduction
In recent years there has been increasing interest in the role of drug transport proteins and, more specifically, how these proteins may impact upon the disposition, efficacy and toxicity of xenobiotics (Glavinas et al., 2004; Oswald et al., 2007) . In parallel with the Phase I and II metabolic enzymes the drug transporter system has evolved to be able to handle the complex chemical set to which humans are exposed (Dean et al., 2001; Hagenbuch and Meier, 2004) . In common with drug metabolising enzymes, drug transporter proteins tend to have wide, overlapping substrate specificities and variable, inducible expression in target tissues, allowing the most efficient response to chemical insult; indeed, transcriptional control of drug transporter protiens is under the control of the same nuclear receptors that regulate drug metabolizing enzyme levels (Staudinger et al., 2003; Plant, 2004; Klaassen and Slitt, 2005) . This control system means that drug transport proteins tend to be expressed at different levels in different tissues, and that this expression level will alter in response to cellular conditions. Examples of this can be seen in pathological conditions such as cancer, where transporter proteins are often over-expressed in tumours (Glavinas et al., 2004) , or in normal tissue following chemical exposure (Nishimura et al., 2006) , both of which can result in decreased chemical access and loss of pharmacological efficacy. Another area of interest, but one that is poorly studied at present is the expression of drug transport proteins in in vitro systems, with recent work focussing on the characterization of drug transport levels in vitro for a number of systems (Hilgendorf et al., 2007; Bow et al., 2008; Nishimura and Naito, 2008) . However, to date the impact of this on the total transport capacity of cells has not been examined, nor how this altered transporter expression relative to in vivo This article has not been copyedited and formatted. The final version may differ from this version. In common with drug metabolizing enzymes, many drug transporters show promiscuity in their substrate binding profile, and this has complicated the development of probe substrates. However, a number of fluorescent probes are now emerging that are diagnostic for the activity of groups of transporters, including rhodamine-123 (SLCO1A, ABCG and ABCC sub-families (Katayama et al., 2007; Perriere et al., 2007) ) and carboxydichlorofluorescein (SLCO1A and ABCC subfamilies (Sun et al., 2001; Zamek-Gliszczynski et al., 2003; Lengyel et al., 2008) ), allowing the establishment of kinetic parameters of drug transport for a number of model substrates (Zamek-Gliszczynski et al., 2003; Pratt et al., 2006) .
Such a data rich environment is thus open to in silico modelling of transport
processes, allowing estimations of the biological importance of these processes, and the predictive nature of in vitro systems with respect to compound disposition. Such systems modelling have traditionally followed either a top-down or bottom-up approach; in the former, all data at one (or more) biological level is incorporated into a comprehensive model, whereas bottom-up modelling focuses on a single aspect in detail. Top-down modelling has had considerable success in less complex organisms such as bacteria or yeast (Beste et al., 2007) , but models in higher eukaryotes tend to be descriptive rather than quantitative in nature (Oda et al., 2005) . To achieve quantitative models of higher organisms bottom-up approaches have been more usually applied, including the examination of membrane transport processes at both the theoretical (Ofer et al., 2006; Bartholome et al., 2007) and practical (Sun and Pang, 2008; Sun et al., 2008) Using a bottom-up systems biology approach we have created the first model of a complete transport process in primary rat hepatocytes, including both apical and basolateral transport. Using this model we show that ABCC2 levels are a fragile node controlling the disposition of the tool substrate carboxydichlorofluroscein (CDF), and that the alteration in ABCC2 expression between in vitro and in vivo has a significant impact on CDF flux through hepatocytes.
Materials and Methods
Primary rat hepatocyte culture: Freshly isolated rat liver was obtained in ice-cold saline from Han-Wistar rats of approximately 300g in weight; only male rats' liver was used in order to mitigate the known variation in expression of drug transporter proteins between the sexes (Lu and Klaassen, 2008) . Primary hepatocytes were isolated using a modification of the protocol of Seglen (Seglen and Jervell, 1969) , followed by enrichment of live cells using Percoll gradient centrifugation.
Primary rat hepatocytes were plated in collagen-coated 6 well plates at a 1.5x10 6 cells per well, and overlaid with matrigel (BD Biosciences, Oxford, UK) to form a sandwich culture. Cells were culture in Williams E medium, supplemented with 100 U/ml penicillin, 100 μ g/ml streptomycin, 0.17 μM insulin, 0.03 μM dexamethasone, 50 μ g/ml gentamycin and 1 % (v/v) 1 M Hepes Carboxydichlorofluroscein Diacetate Assay: CDFDA is a non-fluorescent chemical that can passively diffuse into cells, with a logP=2.8. Once within cells it is converted by intracellular esterases to the metabolite CDF, which is a fluorescent substrate for ABCC transporters (Zamek-Gliszczynski et al., 2003) . This article has not been copyedited and formatted. The final version may differ from this version. Medium was aspirated from cells and they were washed with HBSS. This wash was repeated and the cells were returned to the incubator for 10 minutes covered in HBSS.
After removal of the HBSS, the appropriate working solution of CDFDA was added to the cells, or vehicle control (0.1 % DMSO), and cells incubated at 37 °C as required. Cells were washed three times with HBSS and an image was taken at 10 x magnification using as Axiovert 200 microscope. During imaging cells were exposed to an excitation wavelength of 480 nm using a FITC filter for 2 seconds, followed by quantitation at 530 nm using Axiovert 4.5 software suite.
Transcript level measurement:
Primers and TAMRA/FAM dual labelled probe specific for ABCC2, ABCC3, SLCO1A1, SLCO1A4, SLCO1B2 and 18s were designed using the Primer Express software (Applied Biosystems, Warrington, UK) and were purchased from MWG (Milton Keynes, UK).
Primary rat hepatocytes were plated in collagen-coated 6 well plates at a concentration of 1.5x10 6 cells per well, and overlayed with matrigel (BD Biosciences, Oxford, UK) to form a sandwich culture. Cells were culture in Williams E medium, supplemented with 100 U/ml penicillin, 100 μ g/ml streptomycin, 0.17 μM insulin, 0.03 μM dexamethasone, 50 μ g/ml gentamycin and 1 % (v/v) 1M Hepes. At specified time points, total RNA was isolated from quadruplicate samples using the RNeasy Mini kit (Qiagen) and was quantified using a Nanodrop Agilent 2100
Bioanalyser. (Hucka et al., 2003) Simulations of created networks are then undertaken using the Jarnac Simulation Service (v2.26b), accessed through the Systems Biology Workbench module (Deckard et al., 2006) .
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Results
Generation of in silico model of CDF transport in primary rat hepatocytes.
In order to generate a comprehensive model of CDFDA/CDF flux in primary rat hepatocytes it was first necessary to generate a qualitative model of interactions that occurs, or may possibly occur, upon which kinetic parameters can be built. Figure 1 shows the initial model generated from known interactions of CDFDA and CDF with cellular systems. Following construction of the in silico model, and its validation against in vitro data, we wished to examine if the model could simulate pharmacological modulation of the pathway. To examine this we used MK571, a potent pan-ABCC inhibitor (Gekeler et al., 1995) : Exposure of sandwich cultures of primary rat hepatocytes to DMD #22921 11 plot (figure 3b) allows the derivation of Ki = 3.5±0.1μM. From these derived data it is possible to predict the effect of inhibitor of all species within the network, as seen in figure 3c . Addition of 10 μM MK571 results in a slowing of flux through the system, resulting in increased levels of intracellular CDF, producing an increase in AUC of s5
(intracellular CDF) of 503 %, with a concomitant increase in Cmax by 179 %.
Drug transport protein levels differ significantly between primary cells in vitro and in vivo
One potential use of in silico modelling is to simulate, and understand, differences between in vitro and in vivo systems, allowing more accurate extrapolation of data from initial screens to pre-clinical testing. To examine how differences in expression levels of drug transport proteins could affect the disposition of chemicals in these two systems we next measured levels of all influx-( Figure 4a ) and efflux- (Figure 4b) transporters implicated in CDF transport within primary rat hepatocytes at the transcript level.
FIGURE 4 ABOUT HERE
In general, influx transporter levels appear suppressed in the sandwich culture system, with transcript levels below 100% of levels in the freshly excised liver used to prepare the cultures. However, following four days of culture, when in vitro experiments are routinely undertaken, SLCO1A1 and SLCO1A4 transcript levels peak to approximate in vivo levels, being 129 % and 119 % respectively, while SLCO1B2 transcript levels are within an order of magnitude of the in vivo transcript levels, being 15% (Figure 4a ). By comparison, ABCC2 and ABCC3 transcript levels in the sandwich culture system are significantly higher than in vivo levels for the first six days of culture, with levels being 8524 % and 1807 % of in vivo transcript levels respectively following four days of sandwich culture. As changes in transcript levels This article has not been copyedited and formatted. The final version may differ from this version. do not always correlate to the protein level, we next assessed the level of these two transporters throughout the culture period via Western blotting, revealing a 4.1-and 2.6-fold variability in ABCC2 and ABCC3 expression levels respectively between three and six days in culture compared to freshly isolated rat liver, which was subsequently used to prepare hepatocytes for the culture experiments (Figure 4b ).
This variability is significantly larger for ABCC2 than ABCC3, and on day four of culture when in vitro experiments are routinely undertaken ABCC2 protein levels are 3.5-fold higher than those observed in vivo, while ABCC3 protein levels are only 2.3-fold higher. As stated earlier, correct localization of drug transporters is as important as their physical presence and hence it is pertinent to note that these protein levels were derived from membrane fraction and not total protein and hence should reflect active protein. These large deviations in transcript levels compared to in vivo rat liver suggest that they may impact upon the disposition of chemicals transported by these ABCC proteins. To examine this, in silico simulations were undertaken using both the base model, which correlates well with the in vitro sandwich culture, and a model adjusted for the lower levels of ABCC2 and ABCC3 in fresh rat liver.
Kinetic simulations of the network using protein levels from either fresh rat liver or hepatocytes sandwich cultured for four days demonstrated the impact of the alteration of efflux transporter levels described above. Examining the net movement through the pathway (from CDFDA in HBSS to CDF in bile cannaliculi) produces a Vmax of 97.6±3 pmoles/min/mg, which is reduced to 28±0.2 pmoles/min/mg when protein levels are adjusted to the lower transporter levels seen in freshly isolated rat liver. In addition, as the ratio of ABCC2:ABCC3 expression is also altered this impacts on the Km of the network, decreasing it from 47.5±6.5 to 27.6±1 μM; taken together this The utility of the in silico system is further shown by its ability to generate inhibition constants. Whereas inhibition is often quoted as an IC50, the value of this is questionable as it is dependent upon not only the inhibitor but also the concentration of the substrate used to measure the IC50. A more generally applicable value is the inhibition constant, Ki, which is substrate concentration independent. However, derivation of a Ki is time consuming and expensive as it requires the generation of IC50 curves over a wide range of substrate concentrations to allow the derivation of a dose ratio, from which the Ki can be derived. From a single piece of experimental data, the IC50 of MK571 at 10μM CDFDA, it is possible to run simulations across a range of both inhibitor and substrate concentrations and derive the Ki. The Ki value for MK571 generated for the in silico system (3.5±0.1 μM) agrees very well with This article has not been copyedited and formatted. The final version may differ from this version. (Paul et al., 1996) .
Such an approach has two important advantages: First, derivation of a Ki value in silico is rapid, and as demonstrated herein, provides a good estimation of Ki when compared to in vitro-derived values. This means that the generated data is robust enough to be used to assess the properties of novel chemicals, and plan in vitro experiments based upon this value, producing a significant increase in workflow efficiency. Second, as the derived Ki is dependent upon multiple simulations across a range of both substrate and inhibitor concentrations its derivation is relatively robust, meaning it can be used to confirm in vitro experiments. From the data shown in Figure 3a it is clear that the derivation of the IC50 is not 100% robust as the data points used are sub-optimal. However, due to the multiple simulations involved in Ki determination these errors are minimised, resulting in a value that closely agrees with an in vitro-derived Ki value (Paul et al., 1996) . In addition, in silico simulation could As the amount of data concerning drug transporter expression and activity increases it is important to be able to place this in a biological context. For example, much information exists on the expression of drug transporters from both the SLCO and ABC families in a number of different cellular models (Hilgendorf et al., 2007; Bow et al., 2008; Nishimura and Naito, 2008) , with such data being used to infer in vitro-in vivo correlations in transporter function. However, to increase the utility of such correlations two improvements would be useful. First, the expression data, which is usually captured at the transcript level, must be confirmed in terms of correctly CDF. It is easy to envisage where such information could be of importance, as it is often these intermediates that either exhibit pharmacological or toxicological activity.
Alterations in the levels of either of these factors could significantly alter the safety/efficacy profile of the compound. A central driver at the discovery/development borderline is the ability to accurately extrapolate data from in vitro screens to pre-clinical, and indeed clinical, scenarios. It can be seen that the model herein begins to address the variance seen between in vitro and in vivo generated data, allowing for correction of differences in protein expression. In addition to the production of correction factors to allow improved extrapolation from in vitro to in vivo the use of in silico modelling allows the testing of nodes within a network to identify those that are fragile; these nodes may represent important points for intervention as they will have the most profound impact on flux through the pathway. One possibility for such intervention is the identification of the proteins whose levels should be altered in vitro to achieve a desired impact on a biological process; this could be the manipulation of cell lines to be more similar to in vivo, Sandwich culture of primary rat hepatocytes: Uptake clearance of CDF into rat hepatocytes = 1.9 ± 0.1 μl/min/mg protein and was inhibited by low temperature (10 μM dose).
Uptake was saturable with and Inhibited by substrates of Oatp's e.g. taurocholate and rifampicin. 
